Treatment Process Of Clinical Depression †MyAssignmenthelp.com

Question: Discuss about theTreatment Process Of Clinical Depression. Answer: According to the report of the World Health Centre, depression is one of the biggest causes of burden for the global society that has caused disability within individuals (Penn and Tracy 2012). With the introduction of anti-depressant, it is possible to bring about revolution within the treatment process of clinical depression. The introduction of the idea of placebo effects is also associated with the popularizing the ideas with that of the placebo effects. According to Ferguson, (2001), the anti-depressant can have both long-terms and short-term effects depending upon the levels of clinical depression. The serotonin is believed to play a major role in controlling the level of human emotions. The deficiency of the same is believed to have major effects into the cause of occurring depression. Nevertheless, the anti-depressant drugs that are used cannot be entirely used to deal with the symptoms related with that of the depression. With most of the important matters related with that of the chemical imbalance that occurs within an individual is believed to be the main cause of mental diseases. The placebo effect is believed to be one of the prime forms of treatment that are used to deal with the chemical imbalance. This new forms of treatment are also believed to have major impact into the psycho-social dysfunctions. It is also possible to deal with the negative side-effects that are associated with the use of psychological and anti-depressant drugs. The social factors that are associated with mental disorders can also be dealt with the placebo effects. References Ferguson, J.M., 2001. SSRI antidepressant medications: adverse effects and tolerability. Primary care companion to the Journal of clinical psychiatry, 3(1), p.22. Penn, E. and Tracy, D.K., 2012. The drugs dont work? Antidepressants and the current and future pharmacological management of depression. Therapeutic advances in psychopharmacology, 2(5), pp.179-188.